![](https://wp-static.smartkarma.com/../assets/uploaded/2023/08/Smartkarma-Insight-Card-Square.png)
- Kelun Pharma’s Preliminary Report: The company reports a net income increase of 28.2% for the first half of 2024.
- Net Income Figures: Preliminary net income reached 1.8 billion yuan.
- Revenue Performance: Preliminary revenue is recorded at 11.8 billion yuan.
- Analyst Ratings: Kelun Pharma has received 14 “buy” ratings, 2 “hold” ratings, and 0 “sell” ratings.
A look at Sichuan Kelun Pharmaceutical Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 3 | |
Dividend | 4 | |
Growth | 5 | |
Resilience | 3 | |
Momentum | 5 | |
OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores analysis, Sichuan Kelun Pharmaceutical shows a promising long-term outlook. With a top-tier score of 5 in Growth and Momentum, the company is positioned for strong future expansion and market performance. Additionally, scoring a respectable 4 in Dividend, investors can potentially benefit from consistent dividend payouts. While Value and Resilience scored at a solid 3, reflecting a fair valuation and decent overall resilience, Sichuan Kelun Pharmaceutical‘s standout performance in Growth and Momentum highlights its potential for continued success in the pharmaceutical industry.
Sichuan Kelun Pharmaceutical Co., Ltd. specializes in manufacturing various pharmaceutical products, including large infusion products, tablets, antibiotics, and traditional Chinese medicine. With a focus on growth and momentum, the company’s high scores in these areas suggest a bright future ahead. Coupled with a decent dividend score, Sichuan Kelun Pharmaceutical‘s overall outlook appears optimistic, positioning it as a company to watch for potential investment opportunities in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars